Literature DB >> 16842171

Serotonin and human cognitive performance.

J A J Schmitt1, M Wingen, J G Ramaekers, E A T Evers, W J Riedel.   

Abstract

In the past decade, experimental studies involving healthy human volunteers have revealed that manipulations of the central serotonin (5-HT) system can produce quite specific changes in cognitive functioning, independent of overt mood changes. Reduced 5-HT turnover is consistently associated with impaired long-term memory functioning. Low 5-HT function may also impair cognitive flexibility and improve focused attention. On the other hand, stimulation of central 5-HT has repeatedly been found to impair performance in a true vigilance task. Currently, there is little evidence for mirrored cognitive changes due to opposite 5-HT manipulations in healthy volunteers. Given the mounting evidence for a role of 5-HT in human cognition, reduced 5-HT function could be directly linked to cognitive disturbances in certain conditions, such as in depression and Alzheimer's Disease (AD). There is evidence that stimulating (i.e. normalizing) 5-HT activity in depression may have specific beneficial effects on cognition, independent of a general relief of depressive symptoms, but this premise needs to be confirmed by larger-scale clinical studies. Recently, a potential role of 5-HT in the cognitive symptoms in AD has been identified, but there is insufficient data to evaluate the effects of 5-HT stimulation on cognitive symptoms in AD. It is concluded that serotonin is a potential target for pharmacological cognition enhancement, particularly for restoration of impaired cognitive performance due to 5-HT dysfunction. Further differentiation of the role of 5-HT in normal and disturbed cognition and evaluation of the effects of 5-HT manipulations in various populations is required to establish the full potential of 5-HT drugs as cognition enhancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842171     DOI: 10.2174/138161206777698909

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  62 in total

Review 1.  PET tracers for serotonin receptors and their applications.

Authors:  J S Dileep Kumar; J John Mann
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2014

2.  Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.

Authors:  Roongpetch Keowkase; Marwa Aboukhatwa; Yuan Luo
Journal:  Neuropharmacology       Date:  2010-04-24       Impact factor: 5.250

3.  Evaluating the role of serotonin on neuropsychological function after breast cancer using acute tryptophan depletion.

Authors:  Diane Von Ah; Todd Skaar; Fredrick Unverzagt; Menggang Yu; Jingwei Wu; Bryan Schneider; Anna Maria Storniolo; Lyndsi Moser; Kristin Ryker; Jennifer Milata; Janet S Carpenter
Journal:  Biol Res Nurs       Date:  2010-12-30       Impact factor: 2.522

4.  Antidepressant Use in the Elderly Is Associated With an Increased Risk of Dementia.

Authors:  Chenkun Wang; Sujuan Gao; Hugh C Hendrie; Joe Kesterson; Noll L Campbell; Anantha Shekhar; Christopher M Callahan
Journal:  Alzheimer Dis Assoc Disord       Date:  2016 Apr-Jun       Impact factor: 2.703

5.  Modulation of 5-HT7 receptor: effect on object recognition performances in mice.

Authors:  Thomas Freret; Eleni Paizanis; Gregory Beaudet; Andreia Gusmao-Montaigne; Gerald Nee; François Dauphin; Valentine Bouet; Michel Boulouard
Journal:  Psychopharmacology (Berl)       Date:  2013-08-31       Impact factor: 4.530

6.  Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.

Authors:  Benjamin Kolisnyk; Mohammed A Al-Onaizi; Pedro H F Hirata; Monica S Guzman; Simona Nikolova; Shahar Barbash; Hermona Soreq; Robert Bartha; Marco A M Prado; Vania F Prado
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

7.  Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses.

Authors:  Ricardo Alvarez-Jimenez; Ellen P Hart; Samantha Prins; Marieke de Kam; Joop M A van Gerven; Adam F Cohen; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

8.  Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia.

Authors:  H K Luckhoff; S Kilian; M R Olivier; L Phahladira; F Scheffler; S du Plessis; B Chiliza; L Asmal; R Emsley
Journal:  Metab Brain Dis       Date:  2019-01-02       Impact factor: 3.584

Review 9.  How Studies of the Serotonin System in Macaque Models of Menopause Relate to Alzheimer's Disease1.

Authors:  Cynthia L Bethea; Arubala P Reddy; Fernanda Lima Christian
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Age-related learning and memory deficits in rats: role of altered brain neurotransmitters, acetylcholinesterase activity and changes in antioxidant defense system.

Authors:  Saida Haider; Sadia Saleem; Tahira Perveen; Saiqa Tabassum; Zehra Batool; Sadia Sadir; Laraib Liaquat; Syeda Madiha
Journal:  Age (Dordr)       Date:  2014-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.